These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Manson AJ; Turner K; Lees AJ Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062 [TBL] [Abstract][Full Text] [Related]
4. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461 [TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. Colzi A; Turner K; Lees AJ J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668 [TBL] [Abstract][Full Text] [Related]
6. Buspirone in the treatment of levodopa induced dyskinesias. Kleedorfer B; Lees AJ; Stern GM J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):376-7. PubMed ID: 2056334 [No Abstract] [Full Text] [Related]
7. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa]. Haas JA; Lakke JP Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202 [No Abstract] [Full Text] [Related]
8. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035 [TBL] [Abstract][Full Text] [Related]
9. ['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine]. Jansen EN; van Laar T Ned Tijdschr Geneeskd; 1990 May; 134(18):889-91. PubMed ID: 2345577 [No Abstract] [Full Text] [Related]
10. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087 [TBL] [Abstract][Full Text] [Related]
11. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias. Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945 [No Abstract] [Full Text] [Related]
12. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601 [TBL] [Abstract][Full Text] [Related]
13. Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease. Steiger MJ; Quinn NP; Marsden CD Mov Disord; 1991; 6(1):91-2. PubMed ID: 2005934 [No Abstract] [Full Text] [Related]
15. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483 [TBL] [Abstract][Full Text] [Related]
16. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Chen JJ; Obering C Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444 [TBL] [Abstract][Full Text] [Related]
17. New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Rajput AH; Rajput A; Lang AE; Kumar R; Uitti RJ; Galvez-Jimenez N Mov Disord; 1998 Sep; 13(5):851. PubMed ID: 9756161 [No Abstract] [Full Text] [Related]
18. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment. Zimmerman TR; Sage JI; Lang AE; Mark MH Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678 [TBL] [Abstract][Full Text] [Related]
19. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135 [TBL] [Abstract][Full Text] [Related]
20. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206 [No Abstract] [Full Text] [Related] [Next] [New Search]